Yeah, still wondering the same... my take is, surely they have or expect to have (with the final 2 patients) 3 or more positive responses, to get a positive trial outcome. that's what all the commentary would imply. Otherwise has it all been as waste of time and money??
My speculation is trial indications are positive and they will look to expand EMD AML trial (or whatever broader trial that becomes) in Europe using the new formula with possibly of this being regulatory trial.. although not sure how that would sit with effect on setting pricing, if pricing is set by first use.
Ann: Zantrene AML trial in Israel advances to Phase 2, page-145
-
- There are more pages in this discussion • 89 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.040(2.86%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.49 | $1.41 | $101.7K | 69.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9216 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 7767 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |